Protagonist Therapeutics Inc(PTGX)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

PTGX Protagonist Therapeutics Inc

休市中 12-20 15:59:59 EST

41.49

+1.95

+4.93%

盘后41.49

+0.000.00%

18:05 EST

最高41.68	最低38.91	成交量236.85万
今开39.01	昨收39.54	日振幅7.01%
总市值24.73亿	流通市值19.78亿	总股本5,960万
成交额9,776万	换手率4.97%	流通股本4,767万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"PTGX","market":"US","secType":"STK","nameCN":"Protagonist Therapeutics Inc","latestPrice":41.49,"timestamp":1734728399999,"preClose":39.54,"halted":0,"volume":2368522,"hourTrading":{"tag":"盘后","latestPrice":41.49,"preClose":41.49,"latestTime":"18:05 EST","volume":497923,"amount":20658825.23,"timestamp":1734735957632},"delay":0,"floatShares":47674242,"shares":59598018,"eps":2.683365,"marketStatus":"休市中","marketStatusCode":7,"change":1.95,"latestTime":"12-20 15:59:59 EST","open":39.01,"high":41.68,"low":38.91,"amount":97763478.824388,"amplitude":0.070056,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":2.683365,"exchange":"NASDAQ","tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1734944400000},"adr":0,"listingDate":1470888000000,"adjPreClose":39.54,"adrRate":0,"preHourTrading":{"tag":"盘前","latestPrice":40.44,"preClose":39.54,"latestTime":"04:23 EST","volume":1,"amount":40.44,"timestamp":1734686615916},"postHourTrading":{"tag":"盘后","latestPrice":41.49,"preClose":41.49,"latestTime":"18:05 EST","volume":497923,"amount":20658825.23,"timestamp":1734735957632},"volumeRatio":3.797789814106556,"impliedVol":0.7547,"impliedVolPercentile":0.8492},"requestUrl":"/m/hq/s/PTGX","defaultTab":"news","newsList":[{"id":"2485261427","title":"Protagonist Therapeutics, Inc.盘中异动 急速上涨5.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=2485261427","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2485261427?lang=zh_cn&edition=full","pubTime":"2024-11-22 22:50","pubTimestamp":1732287056,"startTime":"0","endTime":"0","summary":"北京时间2024年11月22日22时50分，Protagonist Therapeutics, Inc.股票出现异动，股价大幅上涨5.07%。Protagonist Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.56%。Protagonist Therapeutics, Inc.公司简介：Protagonist Therapeutics Inc 是一家临床阶段的生物制药公司，拥有专有技术平台，能够发现和开发新型受限肽候选药物以满足医疗需求。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024112222505698e442b7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024112222505698e442b7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["PTGX","BK4139","LENZ"],"gpt_icon":0},{"id":"2485829812","title":"美国研究综述-CPI Card Group、First Solar、Viking Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2485829812","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2485829812?lang=zh_cn&edition=full","pubTime":"2024-11-22 15:35","pubTimestamp":1732260933,"startTime":"0","endTime":"0","summary":"美国研究综述-CPI Card Group、First Solar、Viking Therapeutics路透11月22日 - 华尔街证券分析师周五调整了对几家美国上市公司的评级和目标价，其中包括 CPI Card Group、First Solar 和 Viking Therapeutics。要点  * BJ's Wholesale Club Holdings Inc BJ.N：TD Cowen将目标价从95美元上调至110美元 * CPI Card Group PMTS.O：D.A. Davidson给予买入评级，目标价36美元 * First Solar Inc FSLR.O：Piper Sandler 将目标价从 245 美元下调至 210 美元 * Monolithic Power Systems MPWR.O：Needham将目标价从950美元下调至600美元 * Viking Therapeutics VKTX.O：B. Riley给予买入评级；目标价109美元以下是路透周五报道的美国公司研究行动摘要。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241122:nL4S3MT0J2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MPWR","SHLS","BJ","EXE","NVDX","NTAP","FLS","ATKR","DDOG","PRTH","FSLR","DE","INSM","NVDU","UMBF","SAH","NVD","NVDS.UK","ROST","NOVA","PTGX","3NVD.UK","WMG","ENPH","AUB","AMP","ESTC","CPRT","NXT","PCOR","NVDS","IBP","RUN","NVDD","PMTS","STEM","INTU","SNVD.UK","EVH","GNRC","UNM","2NVD.UK","VKTX","CWAN"],"gpt_icon":1},{"id":"2482734541","title":"Protagonist Therapeutics, Inc.2024财年第三财季实现净利润-33.21百万美元，同比增加2.64%","url":"https://stock-news.laohu8.com/highlight/detail?id=2482734541","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482734541?lang=zh_cn&edition=full","pubTime":"2024-11-12 00:00","pubTimestamp":1731340829,"startTime":"0","endTime":"0","summary":"11月12日，Protagonist Therapeutics, Inc.公布财报，公告显示公司2024财年第三财季净利润为-33.21百万美元，同比增加2.64%；其中营业收入为4.68百万美元，每股基本收益为-0.54美元。从资产负债表来看，Protagonist Therapeutics, Inc.总负债71.94百万美元，其中短期债务45000.00美元，资产负债比为0.09，流动比率为0.11。机构评级：截至2024年11月12日，当前有8家机构对Protagonist Therapeutics, Inc.目标价做出预测，其中目标均价为54.38美元，其中最低目标价为43.00美元，最高目标价为65.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241112000038a22d0d7a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241112000038a22d0d7a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","PTGX"],"gpt_icon":0},{"id":"2481541559","title":"美国研究综述-信诺、万豪、拉尔夫-劳伦","url":"https://stock-news.laohu8.com/highlight/detail?id=2481541559","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481541559?lang=zh_cn&edition=full","pubTime":"2024-11-05 15:04","pubTimestamp":1730790257,"startTime":"0","endTime":"0","summary":"    路透11月5日 - 华尔街证券分析师周二调整了对几家美国上市公司的评级和目标价，其中包括 Cigna、万豪和 Ralph Lauren。要闻             * Cigna   ：Piper Sandler将目标价从392美元上调至394美元             * 万豪  ：杰富瑞将目标价从 225 美元上调至 251 美元              * Ralph Lauren Corp   ：TD Cowen 将目标价从 208 美元上调至 251 美元              * Vertex Pharmaceuticals Inc   ：丰业银行将目标价从480美元上调至486美元             * Wynn Resorts Ltd   ：摩根大通将目标价从101美元上调至113美元  以下是路透周二报导的美国公司研究报告摘要。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AMG","HIMS","LU1489326972.SGD","BEN","LSCC","CI","FRPT","CSTL","EDIT","FOXA","INSP","SHAK","ILMN","RZLT","BMRN","IE00BZ1G4Q59.USD","MDGL","BWIN","NMRA","MAR","KROS","EGHT","LU1244550221.USD","RL","IRON","FIS","SM","PTGX","ARES","ST","LU0949170772.SGD","SLAB","LU0149725797.USD","CMS","BK4106","EVER","OMI","LU1363072403.SGD","LU0971096721.USD","GKOS","CAMP","LU","LU0320765489.SGD","LU0266512127.USD","ATUS","AWI","NYT"],"gpt_icon":1},{"id":"2481415545","title":"美国研究综述-信诺、万豪、拉尔夫-劳伦","url":"https://stock-news.laohu8.com/highlight/detail?id=2481415545","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481415545?lang=zh_cn&edition=full","pubTime":"2024-11-05 15:04","pubTimestamp":1730790257,"startTime":"0","endTime":"0","summary":"    路透11月5日 - 华尔街证券分析师周二调整了对几家美国上市公司的评级和目标价，其中包括 Cigna、万豪和 Ralph Lauren。要闻             * Cigna   ：Piper Sandler将目标价从392美元上调至394美元             * 万豪  ：杰富瑞将目标价从 225 美元上调至 251 美元              * Ralph Lauren Corp   ：TD Cowen 将目标价从 208 美元上调至 251 美元              * Vertex Pharmaceuticals Inc   ：丰业银行将目标价从480美元上调至486美元             * Wynn Resorts Ltd   ：摩根大通将目标价从101美元上调至113美元  以下是路透周二报道的美国公司研究报告摘要。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AWI","LU1363072403.SGD","NMRA","MDGL","CAMP","EVER","ARES","LU0266512127.USD","CMS","LSCC","ATUS","CI","BEN","SHAK","FIS","OMI","IE00BZ1G4Q59.USD","LU0971096721.USD","RZLT","ST","AMG","KROS","CSTL","GKOS","LU0949170772.SGD","PTGX","SLAB","INSP","ILMN","FOXA","MAR","BWIN","NYT","SM","LU","FRPT","LU0149725797.USD","BMRN","LU1244550221.USD","BK4106","LU0320765489.SGD","EGHT","IRON","LU1489326972.SGD","EDIT","RL"],"gpt_icon":1},{"id":"2480381801","title":"Protagonist Therapeutics Inc    预计每股亏损 62 美分 - 财报前瞻","url":"https://stock-news.laohu8.com/highlight/detail?id=2480381801","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480381801?lang=zh_cn&edition=full","pubTime":"2024-11-02 12:08","pubTimestamp":1730520482,"startTime":"0","endTime":"0","summary":"   * Protagonist Therapeutics Inc    预计将在11月4日公布截至2024年9月30日的业绩报告()，季度收入将有所增长。* 根据LSEG的数据，6位分析师的平均预期显示，这家总部位于加利福尼亚州纽瓦克市的公司预计将实现营收166.7万美元。* LSEG 分析师对 Protagonist Therapeutics Inc 的平均预期是每股亏损 62 美分。* 华尔街对 Protagonist Therapeutics Inc 的 12 个月目标价中位数为 51.50 美元，高于其最新收盘价 46.76 美元。11月2日 - 上一季度业绩。除非另有说明，否则所有数据均以美元为单位。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","PTGX"],"gpt_icon":0},{"id":"2479748364","title":"Protagonist Therapeutics Inc    预计每股亏损 60 美分 - 财报前瞻","url":"https://stock-news.laohu8.com/highlight/detail?id=2479748364","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479748364?lang=zh_cn&edition=full","pubTime":"2024-10-31 11:30","pubTimestamp":1730345445,"startTime":"0","endTime":"0","summary":"   * Protagonist Therapeutics Inc    预计将在11月1日公布截至2024年9月30日的业绩报告()，季度收入将有所增长。* 根据 LSEG 的数据，7 位分析师的平均预期显示，这家总部位于加利福尼亚州纽瓦克市的公司预计将实现收入 214.3 万美元。* LSEG 分析师对 Protagonist Therapeutics Inc 的平均预期是每股亏损 60 美分。* 华尔街对 Protagonist Therapeutics Inc 的 12 个月目标价中位数为 51.00 美元，高于其上次收盘价 47.62 美元。10月31日 - 上一季度业绩。除非另有说明，否则所有数据均以美元为单位。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PTGX","LENZ"],"gpt_icon":0},{"id":"2458590066","title":"Protagonist Therapeutics, Inc.盘中异动 早盘股价大涨5.04%报39.06美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2458590066","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2458590066?lang=zh_cn&edition=full","pubTime":"2024-08-09 23:19","pubTimestamp":1723216776,"startTime":"0","endTime":"0","summary":"北京时间2024年08月09日23时19分，Protagonist Therapeutics, Inc.股票出现异动，股价快速拉升5.04%。Protagonist Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为2.50%。Protagonist Therapeutics, Inc.公司简介：Protagonist Therapeutics Inc 是一家临床阶段的生物制药公司，拥有专有技术平台，能够发现和开发新型受限肽候选药物以满足医疗需求。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240809231936941ffc3b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240809231936941ffc3b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","LENZ","PTGX"],"gpt_icon":0},{"id":"2457841211","title":"Protagonist Therapeutics, Inc.盘中异动 早盘股价大涨5.91%报38.35美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2457841211","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457841211?lang=zh_cn&edition=full","pubTime":"2024-08-07 21:43","pubTimestamp":1723038190,"startTime":"0","endTime":"0","summary":"北京时间2024年08月07日21时43分，Protagonist Therapeutics, Inc.股票出现波动，股价大幅上涨5.91%。截至发稿，该股报38.35美元/股，成交量4.4292万股，换手率0.08%，振幅4.92%。Protagonist Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.88%。Protagonist Therapeutics, Inc.公司简介：Protagonist Therapeutics Inc 是一家临床阶段的生物制药公司，拥有专有技术平台，能够发现和开发新型受限肽候选药物以满足医疗需求。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240807214311af96692f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240807214311af96692f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["PTGX","BK4139","LENZ"],"gpt_icon":0},{"id":"2456269758","title":"Protagonist Therapeutics Inc    预计每股亏损 60 美分 - 财报前瞻","url":"https://stock-news.laohu8.com/highlight/detail?id=2456269758","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2456269758?lang=zh_cn&edition=full","pubTime":"2024-08-03 06:15","pubTimestamp":1722636915,"startTime":"0","endTime":"0","summary":"   * Protagonist Therapeutics Inc    预计在8月5日公布截至2024年6月30日的业绩时，季度收入将有所增长(预计)。* 根据LSEG的数据，5位分析师的平均预期显示，这家总部位于加利福尼亚州纽瓦克市的公司预计将实现800万美元的营收。* LSEG 分析师对 Protagonist Therapeutics Inc 的平均预期是每股亏损 60 美分。* 华尔街对 Protagonist Therapeutics Inc 的 12 个月目标价中位数为 48.00 美元，高于其上一次收盘价 37.36 美元。8月2日 - 上一季度业绩。除非另有说明，否则所有数据均以美元为单位。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PTGX","LENZ"],"gpt_icon":0},{"id":"2456891282","title":"Protagonist Therapeutics, Inc.盘中异动 早盘股价大跌5.72%报35.79美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2456891282","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2456891282?lang=zh_cn&edition=full","pubTime":"2024-08-02 21:31","pubTimestamp":1722605487,"startTime":"0","endTime":"0","summary":"北京时间2024年08月02日21时31分，Protagonist Therapeutics, Inc.股票出现异动，股价急速下挫5.72%。截至发稿，该股报35.79美元/股，成交量7687股，换手率0.01%，振幅0.18%。Protagonist Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.74%。Protagonist Therapeutics, Inc.公司简介：Protagonist Therapeutics Inc 是一家临床阶段的生物制药公司，拥有专有技术平台，能够发现和开发新型受限肽候选药物以满足医疗需求。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240802213127941fd893&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240802213127941fd893&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","PTGX","LENZ"],"gpt_icon":0},{"id":"2455995775","title":"Protagonist Therapeutics Inc    预计每股亏损 60 美分 - 财报前瞻","url":"https://stock-news.laohu8.com/highlight/detail?id=2455995775","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2455995775?lang=zh_cn&edition=full","pubTime":"2024-07-31 04:41","pubTimestamp":1722372104,"startTime":"0","endTime":"0","summary":"   * Protagonist Therapeutics Inc    预计在8月1日公布截至2024年6月30日的业绩报告时，季度收入将有所增长(预计)。* 根据LSEG的数据，5位分析师的平均预期显示，这家总部位于加利福尼亚州纽瓦克市的公司预计将实现800万美元的营收。* LSEG 分析师对 Protagonist Therapeutics Inc 的平均预期是每股亏损 60 美分。* 华尔街对 Protagonist Therapeutics Inc 的 12 个月目标价中位数为 48.00 美元，高于上一交易日的收盘价 38.81 美元。7月30日 - 上一季度业绩。除非另有说明，否则所有数据均以美元为单位。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","PTGX"],"gpt_icon":0},{"id":"2454872666","title":"小摩：维持Protagonist Therapeutics(PTGX.US)评级，由增持调整至增持评级, 目标价由39.00美元调整至48.","url":"https://stock-news.laohu8.com/highlight/detail?id=2454872666","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2454872666?lang=zh_cn&edition=full","pubTime":"2024-07-25 22:07","pubTimestamp":1721916474,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU1032466523.USD","IE00BLSP4452.SGD","PTGX","LU0971096721.USD","IE00B1XK9C88.USD","IE00BBT3K403.USD","BK4516","BK4581","IE00BJTD4N35.SGD","LU1267930490.SGD","LU1261432733.SGD","LU1244550577.SGD","BK4207","LU1119994496.HKD","LU1244550221.USD","LU1914381329.SGD","LU0417517546.SGD","BK4533","BK4504","LU0211326839.USD","LU0310799852.SGD","BK4588","LU0320765646.SGD","LU1084165304.USD","BK4566","LU0234572021.USD","LU1668664300.SGD","IE00B3S45H60.SGD","IE00BKVL7J92.USD","LU1894683264.USD","IE00BHPRN162.USD","LU0149725797.USD","LU1894683348.USD","BK4585","LU0106831901.USD","LENZ","LU0976567544.SGD","LU1670627923.USD","LU1363072403.SGD","IE00BFXG1179.USD","LU0267386448.USD","IE000M9KFDE8.USD","IE00BLSP4239.USD","LU0211331839.USD","IE0034235188.USD","LU","LU1244550494.USD","LU0882574139.USD","IE00B1BXHZ80.USD","BK4534"],"gpt_icon":0},{"id":"2454812044","title":"美国研究综述-爱德华生命科学公司、国民银行控股公司、赛捷治疗公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2454812044","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2454812044?lang=zh_cn&edition=full","pubTime":"2024-07-25 15:21","pubTimestamp":1721892117,"startTime":"0","endTime":"0","summary":"    路透7月25日 - 华尔街证券分析师周四调整了对几家美国上市公司的评级和目标价，其中包括爱德华生命科学公司、国民银行控股公司和赛捷治疗公司。要点             * 爱德华生命科学公司  ：摩根大通将其评级从 \"增持 \"下调至 \"中性\"。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BSX","EBMT","PM","ALGN","NAVI","T","IPG","NBHC","GSHD","LU","KNX","CCS","CYH","PHM","EW","FI","FOR","FCF","CFFN","ODFL","EL","BK4023","FSBW","LU1974910355.USD","LU1119994496.HKD","ITW","GEV","EQT","MC","CCK","LU0187121727.USD","LW","NBBK","PTGX","HCA","DV","HNVR","PPBI","PFSI","CME","PRG","CASH","PB","SAGE","LU1121112475.USD","PT"],"gpt_icon":1},{"id":"2454897339","title":"Protagonist Therapeutics Inc: JP Morgan将目标价从39美元上调至48美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2454897339","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2454897339?lang=zh_cn&edition=full","pubTime":"2024-07-25 12:28","pubTimestamp":1721881700,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU1363072403.SGD","BK4139","BK4127","LU1989772840.SGD","LU1162221912.USD","BK4581","LENZ","LU0098860793.USD","PTGX","LU1989772923.USD","BK4534","IE00BZ1G4Q59.USD","LU1074936037.SGD","LU1668664300.SGD","IE00BKVL7J92.USD","LU0971096721.USD","LU0267386448.USD","BK4588","BK4585","LU0320765646.SGD","BK4504","LU0106831901.USD","LU0314104364.USD"],"gpt_icon":0},{"id":"2453900096","title":"BTIG：维持Protagonist Therapeutics(PTGX.US)评级，由买入调整至买入评级, 目标价由41.","url":"https://stock-news.laohu8.com/highlight/detail?id=2453900096","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2453900096?lang=zh_cn&edition=full","pubTime":"2024-07-24 21:32","pubTimestamp":1721827976,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4139","LENZ","PTGX"],"gpt_icon":0},{"id":"2453021882","title":"美国研究综述-Alphabet、通用电气航空航天、特斯拉","url":"https://stock-news.laohu8.com/highlight/detail?id=2453021882","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2453021882?lang=zh_cn&edition=full","pubTime":"2024-07-24 15:28","pubTimestamp":1721806095,"startTime":"0","endTime":"0","summary":"    路透7月24日 - 华尔街证券分析师周三调整了对几家美国上市公司的评级和目标价，其中包括 Alphabet、通用电气航空和特斯拉。股票条目按字母顺序排列。* A of Smith Corp   ：杰富瑞将目标价从90美元下调至85美元             * A of Smith Corp   ：Stifel将其评级从 \"持有 \"上调至 \"买入\"，目标价从97美元上调至98美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SHW","SLG","GE","LU1989763427.SGD","COF","MANH","BOKF","EIX","GOOG","CALX","IE00BKPKM429.USD","KREF","BK4173","AOS","EFSC","RRR","MEDP","BRO","PMT","PHM","IVZ","LU0211331839.USD","AVY","LU2108987350.USD","PTGX","TSLA","SVV","GPC","IE00BJLML261.HKD","KMB","PCAR","HTLD","CMCSA","GOOGL","HCA","ENVA","DHR","PII","CLF","LU1989763690.USD","EWBC","CSGP","TSLL","MTDR","ALK","PFSI","LU2244417387.USD"],"gpt_icon":1},{"id":"2453052619","title":"Protagonist Therapeutics, Inc.盘中异动 股价大涨5.43%","url":"https://stock-news.laohu8.com/highlight/detail?id=2453052619","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2453052619?lang=zh_cn&edition=full","pubTime":"2024-07-23 23:54","pubTimestamp":1721750095,"startTime":"0","endTime":"0","summary":"北京时间2024年07月23日23时54分，Protagonist Therapeutics, Inc.股票出现异动，股价急速拉升5.43%。Protagonist Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为1.10%。其相关个股中，Azitra Inc、Salarius Pharmaceuticals, Inc.、Adial Pharmaceuticals, Inc涨幅较大，Salarius Pharmaceuticals, Inc.、Azitra Inc、Adial Pharmaceuticals, Inc较为活跃，换手率分别为7159.59%、5424.66%、3430.85%，振幅较大的相关个股有Salarius Pharmaceuticals, Inc.、Azitra Inc、Adial Pharmaceuticals, Inc，振幅分别为366.13%、365.43%、137.74%。Protagonist Therapeutics, Inc.公司简介：Protagonist Therapeutics Inc 是一家临床阶段的生物制药公司，拥有专有技术平台，能够发现和开发新型受限肽候选药物以满足医疗需求。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240723235455af93adf0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240723235455af93adf0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["PTGX","BK4139","LENZ"],"gpt_icon":0},{"id":"2449470378","title":"Protagonist Therapeutics, Inc.盘中异动 急速上涨5.78%报35.67美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2449470378","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2449470378?lang=zh_cn&edition=full","pubTime":"2024-07-08 21:37","pubTimestamp":1720445836,"startTime":"0","endTime":"0","summary":"北京时间2024年07月08日21时37分，Protagonist Therapeutics, Inc.股票出现异动，股价大幅上涨5.78%。Protagonist Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.25%。Protagonist Therapeutics, Inc.公司简介：Protagonist Therapeutics Inc 是一家临床阶段的生物制药公司，拥有专有技术平台，能够发现和开发新型受限肽候选药物以满足医疗需求。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240708213716941f4ebe&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240708213716941f4ebe&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["PTGX","BK4139","LENZ"],"gpt_icon":0},{"id":"2446143505","title":"BUZZ-Protagonist Therapeutics 在标准普尔小型股指数中跃升","url":"https://stock-news.laohu8.com/highlight/detail?id=2446143505","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2446143505?lang=zh_cn&edition=full","pubTime":"2024-06-28 19:41","pubTimestamp":1719574898,"startTime":"0","endTime":"0","summary":"    6月28日 - ** Protagonist Therapeutics  股价盘前上涨10.3%至35.16美元，创两周新高，该公司将于下周加入标准普尔小型股600指数<.SPCY** 据标准普尔道琼斯指数公司称，生物技术公司将在 7 月 3 日周一开盘前取代  Encore Wire    加入标准普尔小型股 600 指数<.SPCY** 意大利电缆制造商普睿司曼  以42亿美元的价格收购了 。** PTGX的主要候选产品 ，包括用于治疗一种罕见血液病的rusfertide和与强生  合作开发的银屑病药物JNJ-2113。** 截至本周四收盘，PTGX 的股价累计上涨了 39%，公司市值达到约 19 亿美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0002270589.USD","LU1267930813.SGD","WIRE","LENZ","IE00B19Z3B42.SGD","LU1280957306.USD","SG9999002224.SGD","LU1059921491.USD","LU1196500208.SGD","JNJ","LU1244550577.SGD","LU1585245621.USD","LU1221951129.SGD","LU2347655156.SGD","SG9999002232.USD","BUZZ","IE00BSNM7G36.USD","LU1261432733.SGD","IE00B1BXHZ80.USD","LU0320765646.SGD","LU0122379950.USD","LU0234572021.USD","LU1032955483.USD","LU0640476718.USD","LU2133065610.SGD","LU1732800096.USD","LU0792757196.USD","LU0912757837.SGD","LU1057294990.SGD","IE00B19Z3581.USD","BK4550","LU1066051498.USD","BK4588","BK4096","LU1162221912.USD","BK4585","LU2468319806.SGD","PTGX","LU0795875086.SGD","BK4139","BK4504","BK4581","LU1023059063.AUD","SG9999001440.SGD","LU1430594728.SGD","LU1032466523.USD","LU1732799900.SGD","BK4592","BK4568","LU1244550494.USD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.protagonist-inc.com","stockEarnings":[{"period":"1week","weight":0.01},{"period":"1month","weight":0.0207},{"period":"3month","weight":-0.1234},{"period":"6month","weight":0.2861},{"period":"1year","weight":0.9199},{"period":"ytd","weight":0.8094}],"compareEarnings":[{"period":"1week","weight":-0.0221},{"period":"1month","weight":0.0006},{"period":"3month","weight":0.0397},{"period":"6month","weight":0.0851},{"period":"1year","weight":0.2499},{"period":"ytd","weight":0.243}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Protagonist Therapeutics, Inc.在特拉华州注册成立于2006年8月22日，总部位于加利福尼亚州米尔皮塔斯。该公司是一家生物制药公司，其基于多肽的新化学实体rusfertide和JNJ-2113（原名PN-235）处于不同的开发阶段，均源自专有的发现技术平台。该公司的临床项目分为两大类疾病：（一）血液学和血液疾病，以及（二）炎症和免疫调节疾病。","yearOnYearQuotes":[{"month":1,"riseRate":0.75,"avgChangeRate":0.049238},{"month":2,"riseRate":0.5,"avgChangeRate":-0.008856},{"month":3,"riseRate":0.375,"avgChangeRate":0.043488},{"month":4,"riseRate":0.25,"avgChangeRate":-0.134309},{"month":5,"riseRate":0.625,"avgChangeRate":0.227575},{"month":6,"riseRate":0.75,"avgChangeRate":0.084918},{"month":7,"riseRate":0.625,"avgChangeRate":0.006308},{"month":8,"riseRate":0.75,"avgChangeRate":0.170306},{"month":9,"riseRate":0.444444,"avgChangeRate":-0.008075},{"month":10,"riseRate":0.333333,"avgChangeRate":0.02359},{"month":11,"riseRate":0.555556,"avgChangeRate":0.069407},{"month":12,"riseRate":0.555556,"avgChangeRate":0.026219}],"exchange":"NASDAQ","name":"Protagonist Therapeutics Inc","nameEN":"Protagonist Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Protagonist Therapeutics Inc(PTGX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Protagonist Therapeutics Inc(PTGX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Protagonist Therapeutics Inc,PTGX,Protagonist Therapeutics Inc股票,Protagonist Therapeutics Inc股票老虎,Protagonist Therapeutics Inc股票老虎国际,Protagonist Therapeutics Inc行情,Protagonist Therapeutics Inc股票行情,Protagonist Therapeutics Inc股价,Protagonist Therapeutics Inc股市,Protagonist Therapeutics Inc股票价格,Protagonist Therapeutics Inc股票交易,Protagonist Therapeutics Inc股票购买,Protagonist Therapeutics Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Protagonist Therapeutics Inc(PTGX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Protagonist Therapeutics Inc(PTGX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}